CategoryOncology

CHICAGO—Adding cetuximab to first-line irinotecan chemotherapy for patients with metastatic colorectal cancer gave a median four months advantage in overall survival as compared with adding bevacizumab. Findings from the German Phase III FIRE study

CHICAGO—Patients with oropharyngeal cancer pose no risk of passing HPV infection to their spouses or partners — according findings presented at the 2013 meeting of the American Society of Clinical Oncology — even though their cancers may have been...

CHICAGO—The first drug to hold advanced uveal melanoma in check — doubling progression-free survival — was announced at the 2013 American Society of Clinical Oncology meeting in Chicago. Dr Richard Carvajal from Memorial Sloan-Kettering Cancer...

LUGANO, SWITZERLAND—Sarah Maxwell and Peter Goodwin report from the 2013 European Multidisciplinary Conference on Thoracic Oncology

LONDON—New and comprehensive data showing that millions of cases of breast cancer could be avoided by treating women at high risk of the disease — but who are not yet ill — with the class of drugs known as selective oestrogen receptor modulators...

WASHINGTON DC—Doctors taking the unusual step of combining two experimental drugs to treat cancers in patients who have mutated BRCA — the gene conferring susceptibility to breast, ovarian and some other solid tumours — found that patients responded...

WASHINGTON DC—Laboratory evidence that giving patients intermittent rather than continuous treatment with cancer drugs could help them overcome drug resistance in cancers such as melanoma was presented at the American Association for Cancer Research...

WASHINGTON DC—A new blood test has detected drug-resistant mutations reliably in patients with gastrointestinal stromal tumour (GIST) helping to guide therapy when first-line drugs had failed. This was in a study using the recently approved agent...

WASHINGTON DC—Gene expression and molecular pathways in head and neck cancer have been identified with reference to The Cancer Genome Atlas in research presented at the American Association for Cancer Research annual conference. The PIK-3CA pathway...

WASHINGTON DC—A new type of immunotherapy has brought responses in children with acute lymphoblastic leukaemia in relapse who had no other options to prevent the progress of this fatal phase of the disease. At the American Association for Cancer...

WASHINGTON DC—Patients with metastatic breast cancer who are HER-2 positive could potentially be treated with the anti-HER-2 conjugated drug, trastuzumab-emtansine (T-DM1), alone — without needing to add chemotherapy. This prediction was made at the...